Restless legs syndrome.

William G Ondo

Review Current neurology and neuroscience reports 2005 15 件の引用

<\/script>\n

`; }, get iframeSnippet() { const domain = 'sleepcited.com'; const params = 'pmid\u003D15987610'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style

Widget powered by . Free, no account required.

Study Design

研究タイプ: Review
対象集団: RLS patients

介入: Restless legs syndrome. Dopaminergic medications
比較対照: None
主要アウトカム: RLS symptom relief
効果の方向: Positive
バイアスリスク: Unclear

Abstract

Restless legs syndrome is a very common and still under-diagnosed neurologic condition that can cause severe morbidity. The pathology centers around central nervous system iron homeostatic dysregulation with subsequent alterations in dopaminergic functioning. Genetic studies will hopefully soon identify specific abnormalities. Treatment of restless legs syndrome with dopaminergic medications is highly effective, although augmentation may occur eventually and require dosing flexibility.

要約

Treatment of restless legs syndrome with dopaminergic medications is highly effective, although augmentation may occur eventually and require dosing flexibility.

Used In Evidence Reviews

A 鉄：むずむず脚症候群

Restless legs syndrome.

Embed This Widget

Study Design

Abstract

要約

Used In Evidence Reviews

Similar Papers

Dopamine and iron in the pathophysiology of restless legs syndrome (RLS).

Restless legs syndrome and pregnancy.

Treatment of restless legs syndrome: an evidence-based review and implications for clinical practice.

Restless legs syndrome: pathophysiology, clinical presentation and management.

Altered brain iron homeostasis and dopaminergic function in Restless Legs Syndrome (Willis-Ekbom Disease).

Guidelines for the first-line treatment of restless legs syndrome/Willis-Ekbom disease, prevention and treatment of dopaminergic augmentation: a combined task force of the IRLSSG, EURLSSG, and the RLS-foundation.